Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H8O6S2 |
Molecular Weight | 204.222 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)CCCS(O)(=O)=O
InChI
InChIKey=MGNVWUDMMXZUDI-UHFFFAOYSA-N
InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9)
Eprodisate (1,3-propanedisulfonate) is a negatively charged, sulfonated molecule of low molecular weight that has structural similarities to heparin sulfate; it is a glycosaminoglycan mimetic that binds to the glycosaminoglycan (GAG) binding site on serum A amyloid (AA) to prevent its interaction with glycosaminoglycan and arrest amyloidosis, or inhibit amyloid deposition. In nonclinical toxicity studies in two animal species (i.e., rat and dog), eprodisate was administered orally at doses of up to 2000 mg/kg/day for 39 weeks: eprodisate showed low toxicity potential at doses several fold higher than the anticipated clinical dose, was well tolerated upon chronic exposure and was found to be nonmutagenic and nonclastogenic. Furthermore, a series of safety pharmacology studies showed that eprodisate does not have any clinically
significant effect on major organ function.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: 111345.0 Gene Symbol: Saa Sources: https://www.ncbi.nlm.nih.gov/pubmed/18671471 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Ethanedisulfonate is degraded via sulfoacetaldehyde in Ralstonia sp. strain EDS1. | 2001 Jul |
|
Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. | 2002 May |
|
Dissimilation of C3-sulfonates. | 2006 Mar |
|
Advances in the treatment of amyloidosis. | 2007 Jun 7 |
|
[Multisystemic amyloidosis in 2007]. | 2007 May |
|
Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? | 2008 Aug |
|
Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? | 2008 Aug |
|
Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. | 2008 Dec 3 |
|
[A new treatment of renal disease in AA amyloidosis...and not only that?]. | 2008 Jan-Feb |
|
[Amyloidosis in rheumatic diseases]. | 2010 |
|
Two cationic metal-organic frameworks based on cadmium and α,ω-alkanedisulfonate anions and their photoluminescent properties. | 2010 Dec 14 |
|
Systemic AA amyloidosis: epidemiology, diagnosis, and management. | 2014 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7585011
Curator's Comment: Animals recieved amyloid enhancing factor (AEF) and an inflammatory stimulus to initiate amyloid development. In the acute model, animals were treated with the test compaund 24 hours after induction, and for the next five days. After the sixth days they were killed and their spleens were assessed for amyloid. Eprodisate sodium (Sodium 1,3-propanedisulphonate) was effective in this model (35+/-6% of amyloid found in the untreated controls). This inhibition of steroidogenesis is not a result of a reduction of hepatic serum A amyloid (SAA).
Swiss white mice 25-30 g; 50 mM in 7-8 ml of drinking water per animal per day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
118998
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
428573
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
DB06405
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
DTXSID4048301
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
21668-77-9
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
C520274
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
100000178030
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
C166957
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
1,3-Propanedisulfonic acid
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
6QFP76V7S7
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111092
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY | |||
|
8630
Created by
admin on Fri Dec 15 16:11:16 GMT 2023 , Edited by admin on Fri Dec 15 16:11:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)